Prevention & lipidsCohort study
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry
- Retrospective cohort study
- registry-based
Authors' conclusion
Our findings indicate that the combination of novel and conventional LLTs significantly improved LDL-C control with a signal of better cardiovascular prognosis in HoFH patients.
Study context
- Population
- Patients with homozygous familial hypercholesterolaemia in the Italian LIPIGEN-FH Registry
- Participants
- 139 patients
- Exposure
- Contemporary LLT follow-up vs 5 years before baseline
Main finding
As reported in the abstract
Annual MACE-plus rate
P = 0.0016
Observational data: associations, not effects.
Further findings
LDL-C · median follow-up 5 years
- LDL-C at baseline (mg/dL, mean ± SD)
- 332 ± 138
- LDL-C at last visit, average (mg/dL)
- 124
- LDL-C reduction
- 58.3% (Pt < 0.001)
- Lowest LDL-C, PCSK9 inhibitors plus lomitapide and/or evinacumab (mg/dL)
- ∼90
Quadruple therapy at last visit
- Patients taking quadruple therapy
- 15.8%
Original publication
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry. Eur J Prev Cardiol. Published 20 February 2024. doi:10.1093/eurjpc/zwae036
Summarised from the published abstract; every number is checked against it